Open access · CC-BY
via OpenAlex
Metformin, an AMPK Activator, Inhibits Activation of FLSs but Promotes HAPLN1 Secretion
Yong Chen, Qiu Fujuan, Beijia Yu, Yanjuan Chen, Fangfang Zuo, Xiaoyu Zhu, Kutty Selva Nandakumar, Changhong Xiao
Molecular Therapy — Methods & Clinical Development · 2020 · ▲ 46 citations
Abstract
AMP-activated protein kinase (AMPK) is essential for maintaining energy balance and has a crucial role in various inflammatory pathways. In this study, AMPK levels positively correlated with many inflammatory indexes in rheumatoid arthritis (RA) patients, especially in the affected synovium. In RA sera, a positive correlation between phosphorylated (p-)AMPK-α1 levels and DAS28 (disease activity score 28) activity (r = 0.270, p < 0.0001) was found. Similarly, a positive correlation was observed between AMPK-α1 and tumor necrosis factor α (TNF-α) levels (r = 0.460, p = 0.0002). Differentially expressed genes between osteoarthritis (OA) and RA synovium from NCBI GEO profiles and our RNA sequencing data suggested activation of metabolic pathways specific to RA-fibroblast-like synoviocytes (FLSs). AMPK-α1 was highly expressed in the synovium of RA but not OA patients. An AMPK activator, metformin, inhibited FLS proliferation at higher but not lower concentrations, whereas the inhibitor dorsomorphin promoted the proliferation of RA-FLSs. Interestingly, both metformin and dorsomorphin inhibited the migration of RA-FLSs. After metformin treatment, expression of interleukin 6 (IL-6), TNF-α, and IL-1β were significantly downregulated in RA-FLSs; however, increased expression of p-AMPK-α1, protein kinase A (PKA)-α1, and HAPLN1 (hyaluronan and proteoglycan link protein 1) was observed. Increased levels of HAPLN1 in RA-FLSs by an AMPK activator could potentially be beneficial in protecting the joints. Hence, our results demonstrate the potential of an AMPK activator as a therapeutic for RA.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1016/j.omtm.2020.05.008
- Canonical
- link ↗
- Fetched
- 2026-10-09 MST
Cite this
APA
Chen, Y., Fujuan, Q., Yu, B., Chen, Y., Zuo, F., Zhu, X., Nandakumar, K.S., & Xiao, C. (2020). Metformin, an AMPK Activator, Inhibits Activation of FLSs but Promotes HAPLN1 Secretion. <em>Molecular Therapy — Methods & Clinical Development</em>. https://doi.org/10.1016/j.omtm.2020.05.008
Vancouver
Chen Y, Fujuan Q, Yu B, Chen Y, Zuo F, Zhu X, et al. Metformin, an AMPK Activator, Inhibits Activation of FLSs but Promotes HAPLN1 Secretion. Molecular Therapy — Methods & Clinical Development. 2020. doi:10.1016/j.omtm.2020.05.008.
BibTeX
@article{yong2020Metfor,
title = {Metformin, an AMPK Activator, Inhibits Activation of FLSs but Promotes HAPLN1 Secretion},
author = {Yong Chen and Qiu Fujuan and Beijia Yu and Yanjuan Chen and Fangfang Zuo and Xiaoyu Zhu and Kutty Selva Nandakumar and Changhong Xiao},
journal = {Molecular Therapy — Methods & Clinical Development},
year = {2020},
doi = {10.1016/j.omtm.2020.05.008},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Journal of Rheumatic Diseases 2016
Open access · OA
Roles of Reactive Oxygen Species in Rheumatoid Arthritis Pathogenesis
Aging and Disease 2020
Open access · CC-BY
Antidiabetic Drug Metformin Ameliorates Depressive-Like Behavior in Mice with Chronic Restraint Stress via Activation of AMP-Activated Protein Kinase
Bone 2026
Citation only
Osteogenic promotion by naringin through the PI3K/AKT/mTOR pathway-mediated activation of autophagy and inhibition of apoptosis.
Journal of Burn Care & Research 2026
Preprint · OA
TMAO Correlates with Transcriptomic Signatures of Leukocyte Activation and Systemic Inflammation Following Burn Injury
Endocrine Journal 2020
Open access · OA
Gender-differential effects on blood glucose levels between acarbose and metformin in Chinese patients with newly diagnosed type 2 diabetes: a sub-analysis of the MARCH trial
Bioengineered 2022
Open access · CC-BY